151 related articles for article (PubMed ID: 37679606)
1. Different patterns of failure in two treatment regimens for primary central nervous system lymphoma, a retrospective analysis of 124 cases in Taiwan.
Chuang CH; Kuo MC; Chang H; Wu JH; Hung YS; Ou CW; Lin TL; Su YJ; Ong YC; Shih LY; Kao HW
Clin Exp Med; 2023 Dec; 23(8):5327-5336. PubMed ID: 37679606
[TBL] [Abstract][Full Text] [Related]
2. Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
Wendler J; Fox CP; Valk E; Steinheber C; Fricker H; Isbell LK; Neumaier S; Okosun J; Scherer F; Ihorst G; Cwynarski K; Schorb E; Illerhaus G
BMC Cancer; 2022 Sep; 22(1):971. PubMed ID: 36088292
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.
Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y
J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986
[TBL] [Abstract][Full Text] [Related]
4. A single institutional retrospective evaluation for younger patients with primary central nervous lymphomas on a modified R-MPV regimen followed by radiotherapy and high dose cytarabine.
Hattori K; Sakata-Yanagimoto M; Okoshi Y; Kato T; Kurita N; Yokoyama Y; Obara N; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Hasegawa Y; Chiba S
J Clin Exp Hematop; 2017 Oct; 57(2):41-46. PubMed ID: 28781291
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
Ghesquieres H; Chevrier M; Laadhari M; Chinot O; Choquet S; Moluçon-Chabrot C; Beauchesne P; Gressin R; Morschhauser F; Schmitt A; Gyan E; Hoang-Xuan K; Nicolas-Virelizier E; Cassoux N; Touitou V; Le Garff-Tavernier M; Savignoni A; Turbiez I; Soumelis V; Houillier C; Soussain C
Ann Oncol; 2019 Apr; 30(4):621-628. PubMed ID: 30698644
[TBL] [Abstract][Full Text] [Related]
6. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma.
Liu CJ; Lin SY; Yang CF; Yeh CM; Kuan AS; Wang HY; Tsai CK; Gau JP; Hsiao LT; Chen PM; Liu YC; Hong YC; Ko PS; Liu JH; Lin CH
Cancer Med; 2020 Mar; 9(6):2134-2145. PubMed ID: 32011103
[TBL] [Abstract][Full Text] [Related]
7. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
8. Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients.
Zeremski V; Adolph L; Beer S; Berisha M; Jacobs B; Kahl C; Koenecke C; Kropf S; Panse J; Petersen J; Schmidt-Hieber M; Schneider J; Vucinic V; Walter J; Weigert O; Witte HM; Mougiakakos D
Eur J Haematol; 2024 Apr; 112(4):641-649. PubMed ID: 38164819
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Autologous Stem Cell Transplantation as a Consolidative Strategy for the Treatment of Primary and Isolated Secondary Central Nervous System Diffuse Large B Cell Lymphomas.
Sahin U; Gokmen A; Soydan E; Urlu SM; Merter M; Gokgoz Z; Arslan O; Ozcan M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e1-e13. PubMed ID: 36344419
[TBL] [Abstract][Full Text] [Related]
10. [Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].
Song J; Liu H; Shen HL; Yue LZ; Yang XJ; Song WJ; Sun CY; Yu SZ; Ding K; Wang YH; Li LJ; Yu H; Shao YY; Wang CM; Yue SY; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):917-922. PubMed ID: 35045653
[No Abstract] [Full Text] [Related]
11. Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma.
Song MK; Chung JS; Joo YD; Lee SM; Oh SY; Shin DH; Yun EY; Kim SG; Seol YM; Shin HJ; Choi YJ; Cho GJ
J Neurooncol; 2011 Sep; 104(3):825-31. PubMed ID: 21380743
[TBL] [Abstract][Full Text] [Related]
12. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
13. MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma.
van der Meulen M; Dirven L; Bakunina K; van den Bent MJ; Issa S; Doorduijn JK; Bromberg JEC
J Neurooncol; 2021 Apr; 152(2):357-362. PubMed ID: 33611761
[TBL] [Abstract][Full Text] [Related]
14. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
[TBL] [Abstract][Full Text] [Related]
15. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
[TBL] [Abstract][Full Text] [Related]
16. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.
David KA; Sundaram S; Kim SH; Vaca R; Lin Y; Singer S; Malecek MK; Carter J; Zayac A; Kim MS; Reddy N; Ney D; Habib A; Strouse C; Graber J; Bachanova V; Salman S; Vendiola JA; Hossain N; Tsang M; Major A; Bond DA; Agrawal P; Mier-Hicks A; Torka P; Rajakumar P; Venugopal P; Berg S; Glantz M; Goldlust SA; Folstad M; Kumar P; Ollila TA; Cai J; Spurgeon S; Sieg A; Cleveland J; Chang J; Epperla N; Karmali R; Naik S; Martin P; Smith SM; Rubenstein J; Kahl B; Evens AM
Am J Hematol; 2023 Jun; 98(6):900-912. PubMed ID: 36965007
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
18. Prognostic value of POD18 combined with improved IELSG in primary central nervous system lymphoma.
Du KX; Shen HR; Pan BH; Luthuli S; Wang L; Liang JH; Li Y; Yin H; Li JY; Wu JZ; Xu W
Clin Transl Oncol; 2024 Mar; 26(3):720-731. PubMed ID: 37558851
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological Features and Outcomes in Primary Central Nervous System Lymphoma: A 10-year Experience.
Puligundla CK; Bala S; Karnam AK; Gundeti S; Paul TR; Uppin MS; Maddali LS
Indian J Med Paediatr Oncol; 2017; 38(4):478-482. PubMed ID: 29333016
[TBL] [Abstract][Full Text] [Related]
20. The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma.
Cho H; Chang JH; Kim YR; Kim SJ; Chung H; Park H; Lee JY; Jang JE; Kim Y; Kim SH; Yang WI; Suh CO; Cheong JW; Min YH; Kim JS
Br J Haematol; 2016 Aug; 174(3):444-53. PubMed ID: 27018207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
